• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Vertex Pharmaceuticals Could See More Gains but Weaker Momentum Is a Risk

The pace of the rally in the drugmaker's shares is slowing, which is one reason to keep an eye on its stock.
By BRUCE KAMICH
Feb 21, 2020 | 08:16 AM EST
Stocks quotes in this article: VRTX

While investors continue to discount the seriousness of the coronavirus, Jim Cramer said he's looking for what the industry calls "uncorrelated returns," or stocks that can deliver no matter what happens with the Covid-19 outbreak. One way to get uncorrelated returns is with biotech, Cramer said during Thursday's "Mad Money" program, and cited Vertex Pharmaceuticals Inc. (VRTX) , a stock that's up 30% over the last 12 months.

Vertex's drug for cystic fibrosis, Trikafta, was approved last October and the company rushed it to patients. Analysts had forecast sales of $95 million for Trikafta last quarter, but Vertex stunned the Street with sales of $420 million. Its bottom line also bashed forecasts, with Vertex delivering earnings per share of $1.70. Vertex has several other drugs in development.

Let's check out the charts of VRTX.

In this daily bar chart of VRTX, below, we can see that prices made a sideways consolidation pattern from at least February to early October. From early October VRTX and the broad market took off to the upside. Prices are above the riising 50-day moving average line and the rising 200-day moving average line. We can see a bullish golden cross of these two averages back in early November.

The daily On-Balance-Volume (OBV) line also shows a strong move higher from October. The rising OBV line tells us that buyers of VRTX have been more aggressive and this information helps to support a bullish view on the stock. The 12-day price momentum study in the lower panel shows lower momentum peaks from late October, which tells us that the pace of the advance has slowed over time. This is a bearish divergence when compared to the price action. A bearish divergence is not a clear-cut sell signal, but it is a reason to watch the stock much closer.

In this weekly bar chart of VRTX, below, we can see that prices broke out on the upside from a much longer consolidation pattern than what we saw above on the daily chart. Prices are above the rising 40-week moving average line. The weekly OBV line turned upward with the price action and helps to confirm the price gains. The 12-week momentum study shows that momentum is weakening or that the pace of the rally is slowing. Again, another technical heads up to keep an eye on from here.

In this daily Point and Figure chart of VRTX, below, we can see that prices have reached an upside price target in the $247 area. Further gains are possible, but we need to keep this in mind.

In this weekly Point and Figure chart of VRTX, below, we can see a potential price target of $271,

Bottom line strategy: VRTX is still in an uptrend with no glaring reasons to sell. Raise sell stops to a close below $230 and think about becoming a scale-up profit taker/seller toward $270.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Earnings | Investing | Stocks | Technical Analysis | Pharmaceuticals | Mad Money | Real Money

More from Stocks

Does the Big Bounce Mean More to Come? Let's See What Drove the Move

James "Rev Shark" DePorre
Jun 24, 2022 4:42 PM EDT

Much of the rally can be attributed to structural reasons, not fundamentals, technicals, or even macro ones.

MongoDB Is Poised for a Rally

Bruce Kamich
Jun 24, 2022 2:15 PM EDT

Here's our initial upside price target for MDB which provides a general purpose database platform.

See That Down the Road? It's the Big 'Green' Bubble, Ready to Pop

Jim Collins
Jun 24, 2022 1:30 PM EDT

Environmental, social, and corporate governance has created a monster and gullible investors should hit the brakes on their EVs and run from the Washington technocrats while they have the chance.

When Times Are Tough, These 3 Mega-Caps Should Deliver the Dividends

Bob Ciura
Jun 24, 2022 1:00 PM EDT

Here's why in recessions and bear markets, the right mega-cap stocks can offer security -- and good yields.

Atlassian Is Now in the Latter Stages of Its Decline

Bruce Kamich
Jun 24, 2022 12:22 PM EDT

Let's check the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login